Recommendations for appropriate sublingual immunotherapy clinical trials

Area of Science:

• Allergy and immunology research
• Clinical trial methodology

Background:

• Sublingual immunotherapy (SLIT) is a recognized alternative to subcutaneous immunotherapy for allergies.
• Existing evidence for SLIT efficacy is derived from 77 clinical trials and 7 meta-analyses.
• Significant heterogeneity across studies in doses, regimens, patient selection, and reporting weakens the evidence base.

Purpose of the Study:

• To highlight the need for harmonizing methodologies in sublingual immunotherapy clinical trials.
• To address challenges in comparing SLIT efficacy due to study variations and inconsistent reporting.
• To emphasize the importance of standardized trial designs for interpretable and comparable data.

Main Methods:

• Review of existing clinical trials and meta-analyses on sublingual immunotherapy.
• Analysis of heterogeneity factors including study design, treatment parameters, and outcome reporting.
• Consideration of variability in allergen extract potency and adverse event classification.

Main Results:

• Evidence for SLIT efficacy is substantial but weakened by considerable study heterogeneity.
• Inconsistency in reporting doses, regimens, patient selection, and outcomes impedes direct comparisons.
• Variability in allergen extract potency and adverse event reporting further complicates data interpretation.

Conclusions:

• Harmonization of methodology, outcome measures, and reporting in SLIT clinical trials is essential.
• Standardized approaches will enable more reliable comparisons of treatment efficacy across studies.
• Recent recommendations from international societies and the World Allergy Organization aim to improve trial design and data homogeneity.